Hydromer Reports 11% Revenue Growth and Return to Profitability in Q3 2025

Hydromer, Inc., a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices, announced certain preliminary, unaudited financial results for the quarter ended September 30, 2025. The company reported revenue of $0.91 million, representing an 11% increase compared to $0.81 million in the third quarter of 2024. This growth demonstrates the company's continued market traction and expanding customer base in the medical device coating sector.

The company reported a net income of $53,000 in the third quarter, marking a return to profitability after previous quarters. This financial performance indicates improved operational efficiency and successful execution of the company's business strategy. Michael Torti, CEO of Hydromer, stated that the company maintains a high level of customer loyalty and is beginning to see growth from new customers entering its production coating line-up.

Hydromer continues to invest in infrastructure and equipment needs while focusing heavily on new product development. The company's commitment to building a scalable, innovation-driven platform positions it for sustained growth in the competitive medical device coating market. The company's long-standing expertise in surface modification technologies, developed over more than 44 years, provides a solid foundation for future expansion and technological advancement.

The company also addressed challenges with its stock valuation and trading difficulties, announcing plans to return HYDI to the OTCID Basic Market. This strategic move could potentially improve market accessibility and valuation for investors interested in the specialized medical coating sector. The company's forward-looking statements emphasize continued prioritization of operational efficiency, customer partnerships, and next-generation technology development.

Hydromer's ISO 9001:2015 certification and compliance with Good Manufacturing Practice (GMP), International Organization for Standardization (ISO) 13485, and International Organization for Standardization (ISO) 9001 standards underscore its commitment to quality and regulatory compliance in serving global markets. The company's diverse service offerings, including proprietary coating formulations, custom coating services, research and development, analytical testing, and technology transfer, provide comprehensive solutions for medical device manufacturers worldwide. View the original release on https://www.newmediawire.com.